Related Experiment Video
Updated: Apr 23, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
rs11613352 polymorphism (TT genotype) associates with a decrease of triglycerides and an increase of HDL in familial
Rosa Aledo1, Teresa Padró1, Pedro Mata2
1Centro de Investigación Cardiovascular, CSIC-ICCC, IIBSant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
The rs11613352 single nucleotide polymorphism is linked to lower triglyceride and higher high-density lipoprotein cholesterol levels in familial hypercholesterolemia patients. This finding may help in managing cardiovascular risk in this high-risk population.
Area of Science:
- Genetics
- Cardiovascular Disease
- Lipid Metabolism
Background:
- Genome-wide association studies identified a locus on chromosome 12q13.3 associated with lipid levels.
- The single nucleotide polymorphism (SNP) rs11613352 is the lead SNP in this region.
- Familial hypercholesterolemia (FH) is a condition characterized by high cardiovascular risk due to elevated cholesterol.
Purpose of the Study:
- To investigate the role of the rs11613352 SNP in a cohort of FH patients.
- To determine the association between rs11613352 and plasma lipid levels in FH.
Main Methods:
- Genotyping of rs11613352 using Taqman assay in 601 FH patients.
- Analysis of association with triglyceride and high-density lipoprotein cholesterol levels using multivariate linear regression.
Main Results:
- The rs11613352 polymorphism showed a recessive association (TT genotype).
- The TT genotype was significantly associated with decreased triglyceride levels (P=.002).
- The TT genotype was significantly associated with increased high-density lipoprotein cholesterol levels (P=.021) after adjusting for age and sex.
Conclusions:
- The rs11613352 SNP may influence cardiovascular risk in FH patients.
- Modulation of plasma lipid levels by rs11613352 could impact cardiovascular risk in FH.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Genetic Lingo
Huntington Disease l: Introduction

